Post-earnings recap
Reported
Thu, Aug 10, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
CRISPR Therapeutics did not meet expectations for earnings per share, but the stock rose by 1.31% following the report. Investors may be optimistic about the company's ongoing clinical programs despite the lack of revenue details. The overall sentiment seems to reflect confidence in the company's long-term potential.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.56 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management emphasized their commitment to ongoing clinical development. They did not provide detailed guidance for future performance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company remains focused on advancing its clinical programs.